Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Compugen logo — A clinical-stage cancer immunotherapy company and a pioneer...

Compugen

A clinical-stage cancer immunotherapy company and a pioneer in computational target discovery

Founded 1993 Israel Israel 112 employees IPO Total: $126.00M Analytics, Biotechnology +3

General Information

Company Name Compugen
Founded Year 1993
Location Israel Israel
Employees 112
Industries Analytics, Biotechnology, Computing +2
Funding Stage IPO
Business Model B2B
Revenue Model Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Compugen. To contact Compugen, visit cgen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Compugen compare?

A PDF of Compugen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Compugen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Compugen

Compugen is a clinical-stage company specializing in cancer immunotherapy, leveraging its AI/ML-powered computational discovery platform, Unigen™. Founded in 1993, this Israel-based firm is recognized for its pioneering role in computational target discovery.

Compugen's innovative pipeline includes proprietary programs targeting TIGIT, such as COM902, a high-affinity anti-TIGIT antibody in Phase 1, and rilvegostomig, an antibody in Phase 3 via a license with AstraZeneca. Additionally, their early-stage assets, COM701 and GS-0321 (licensed to Gilead), underline the potential to redefine cancer immunotherapy by exploring novel biological pathways.

Listed on Nasdaq and the Tel Aviv Stock Exchange under CGEN, Compugen secured its latest funding of $20.00M through a Post-Ipo Equity investment in November 2021 from Bristol-Meyers Squibb. This financial backing and strategic partnerships position Compugen as a promising contender in the biotechnology sector, targeting the immune system to combat cancer effectively.

Business keywords: Cancer Immunotherapy, Computational Target Discovery, AI/ML Powered Discovery, Fc-reduced Antibodies, Bispecific Antibody Development, TIGIT Targeting Programs, PD-1/TIGIT Bispecific Antibodies, Immuno-Oncology, In Silico Prediction, Pharmaceutical Partnerships, Machine Learning Systems, Drug Development Pipeline, Therapeutic Discovery, In Silico Hypothesis-Driven Discovery, Experimental Validation

Services & Products

Drug Discovery
Clinical Trials
Therapeutic Development
AI/ML Application in Drug Research

Target Customers

Pharmaceutical Companies Biotech Investors Healthcare Providers Cancer Research Organizations Oncology Researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $20.00M 1
Bristol-Meyers Squibb
Bristol-Meyers Squibb
01 Nov 2021
Post-IPO Equity $79.00M -
01 Mar 2020
Post-IPO Equity $12.00M 1
Bristol-Meyers Squibb
Bristol-Meyers Squibb
01 Oct 2018
IPO Undisclosed -
01 Jul 2000
IPO Undisclosed -
01 Jan 2000
Early VC $15.00M 2
American Capital Paolim Capital Markets
American Capital, Paolim Capital Markets
01 Dec 1998

Compugen Alternatives & Competitors

View All Alternatives
Compugen vs
Arcus Biosciences
Arcus Biosciences United States

Global, biopharmaceutical company at the forefront of designing precision combinations in the pursui...

IPO
646 employees
Biopharma, Biotechnology
Compare Compugen vs Arcus Biosciences
Compugen vs
Hummingbird Bioscience
Hummingbird Bioscience Singapore

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformat...

Series C
82 employees
Biotechnology, Health Care
Compare Compugen vs Hummingbird Bioscience
Compugen vs
Valink Therapeutics
Valink Therapeutics United States

Making better ADCs

Seed
31 employees
Biotechnology, Health Care
View all alternatives

FAQ About Compugen

A clinical-stage cancer immunotherapy company and a pioneer in computational target discovery
Compugen was founded in 1993.
Compugen is headquartered in Israel.
Compugen operates in Analytics, Biotechnology, Computing, Health Care and Information Technology. Its work centres on Cancer Immunotherapy, Computational Target Discovery, AI/ML Powered Discovery and Fc-reduced Antibodies. Its customers include Pharmaceutical Companies, Biotech Investors and Healthcare Providers.
Compugen has a B2B business model. Its revenue comes from Licensing and Performance Based.
Compugen has approximately 112 employees.
Compugen has completed 6 funding rounds, raising a total of $126.00M. The latest funding stage is IPO.
Compugen offers: Drug Discovery, Clinical Trials, Therapeutic Development, AI/ML Application in Drug Research.
Top alternatives and competitors to Compugen include Arcus Biosciences, Hummingbird Bioscience, Valink Therapeutics, Sibylla Biotech, BioArdis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Compugen and Arcus Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Compugen, https://bouncewatch.com/company/compugen, updated 22 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes